Cocrystals of flavonoids with 4,4′-ethylenebispyridine: Crystal structures analysis, dissolution behavior, and anti-tumor activity

Organic-inorganic Hybrid Perovskite-Based Light-Assisted Li-oxygen Battery with Low Overpotential

Organic-inorganic hybrid perovskites have emerged in the last decade as promising semiconductors due to the excellent optoelectronic properties. This kind of perovskites exhibited respectable photocatalytic activities toward potential application in battery; however, the instability issue still hindered their practical use. Herein, a hybrid perovskite material, 4,4'-ethylenedipyridinium lead bromide [(4,4'-EDP)Pb₂ Br₆ ], was assembled onto the carbon materials to function as photoelectrode of the Li-oxygen battery. The strong cation-π interactions between the A-site cations enabled this hybrid perovskite to endure the cycling process as well as the exposure to battery electrolyte and oxygen. Benefitting from the photo-generated carriers of the photoelectrode under illumination, the formation/decomposition of the discharge product was accelerated, thus leading to a reduced overpotential from 1.3 V to an optimized 0.5 V compared to the Li-oxygen battery without illumination. The overpotential could be maintained lower than 0.9 V after cycling for 170 h. Furthermore, when exposed to the sunlight, the charging voltage was reduced by over 0.2 V. The intrinsic stability and strong light absorption of perovskites together with the optimized perovskite/carbon cathode interfaces contributed to the improved performance under different light sources without complex material design, which shed light on the exploration of organic-inorganic hybrid perovskites in Li-oxygen battery applications.

Design and Synthesis of Carbothioamide/Carboxamide-Based Pyrazoline Analogs as Potential Anticancer Agents: Apoptosis, Molecular Docking, ADME Assay, and DNA Binding Studies

To discover anticancer drugs with novel structures and expand our research scope, pyrazoline derivatives (3a-3l) were designed and synthesized through cyclization of chalcones with thiosemicarbazide/semicarbazide in CH₃COOH as a solvent. All newly synthesized pyrazoline derivatives were fully characterized using several spectroscopic experiments such as ¹H, ¹³C NMR, FT-IR spectroscopy, and mass analysis. By HPLC, the purity of all analogs was found above 95% and both lead compounds (3a and 3h) were also validated by HRMS. Anticancer activity of synthesized pyrazoline derivatives (3a-3l) was investigated by the MTT assay against the human lung cancer cell (A549), human cervical cancer cell (HeLa), and human primary normal lung cells (HFL-1). Staurosporine (STS) was used as a standard drug. The anticancer results showed that two potent analogs 3a and 3h exhibit excellent activity against A549 (IC₅₀ = 13.49 ± 0.17 and 22.54 ± 0.25 μM) and HeLa cells (IC₅₀ = 17.52 ± 0.09 and 24.14 ± 0.86 μM) and low toxicity against the HFL-1 (IC₅₀ = 114.50 ± 0.01 and 173.20 ± 10 μM). The flow cytometry was further used to confirm the anticancer activity of potent derivatives against the A549 cancer cell line. DNA binding interaction of anticancer agents 3a and 3h with Ct-DNA has been carried out by absorption, fluorescence, EtBr (dye displacement assay), circular dichroism, cyclic voltammetry and time-resolved fluorescence, which showed noncovalent binding mode of interaction. Anticancer activity of both lead compounds (3a and 3h) may be attributed to DNA binding. The evaluation of the antioxidant potential of pyrazoline analogs 3a and 3h by 2,2-diphenyl-1-picrylhydrazyl free radical showed promising antioxidant activity with IC₅₀ values of 0.132 ± 0.012 and 0.215 ± 0.025 μg/mL, respectively. In silico molecular docking of pyrazoline derivatives was also performed using autodock vina software against the DNA hexamer with PDB ID: 1Z3F and ADMET properties to explore their best hits.